Jyothy Labs announced on June 15, 2026, that it will pursue legal remedies following discussions with Henkel AG & Co. KGaA regarding the non-renewal of the Pril and Fa brands. After evaluating all options, the company concluded that legal action is necessary to assert its contractual rights concerning the exit and transition mechanism under existing agreements.
Jyothy Labs Initiates Legal Proceedings
Jyothy Labs Limited has officially communicated its intention to pursue legal remedies in relation to the non-renewal of the Pril and Fa brands. This decision follows a period of discussions and communication with Henkel AG & Co. KGaA. The company stated on June 15, 2026, that it has evaluated all available options and concluded that legal action is the appropriate course to assert its contractual rights concerning the exit and transition mechanism under the established License Agreements and Technology License Agreements.
Background of the Agreement
The initial agreement, executed on May 31, 2011, involved License Agreements and Technology License Agreements for the manufacturing, distribution, marketing, and sale of products under the Pril and Fa brands. The parties involved were Erstwhile Henkel India Limited (now amalgamated with Jyothy Labs Limited) and Henkel AG & Co. KGaA.
Board Decision and Future Developments
The Board of Directors of Jyothy Labs Limited convened earlier today and, based on the outcome of their deliberations, made this disclosure. The company has assured that it will keep the Stock Exchanges informed of any further material developments regarding this matter.
The company is committed to asserting its contractual rights and ensuring a fair resolution based on the terms of the agreements.
Source: BSE
